Introduction
============

Norepinephrine used in clinical routine to increase cerebral perfusion following severe traumatic brain injury (TBI) may activate α~2~-adrenergic receptors on platelets, thereby possibly promoting formation of microthrombosis and inducing additional brain injury.

Methods
=======

Arterial and jugular venous platelets isolated from norepinephrine-receiving TBI patients (*n*= 11) and healthy volunteers (*n*= 36) (cubital vein) were stimulated *in vitro*with increasing norepinephrine concentrations (10 nM to 100 μM); thrombin receptor activator peptide (TRAP) served as positive control. P-selectin expression was determined by flow cytometry (FACS).

Results
=======

Following TBI, the number of unstimulated P-selectin-positive platelets was significantly decreased in the second week by 60%. During the first week, the *in vitro*stimulatory effect was significantly reduced; in the second week, however, norepinephrine-mediated effects exceeded changes in controls and the first week without a difference between arterial and jugular venous platelets (Figure [1](#F1){ref-type="fig"}).
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Conclusion
==========

Clinically relevant norepinephrine concentrations are \<25 nM. The present *in vitro*effects occurred at concentrations \>500 nM. Thus, a clinically relevant impact appears doubtful.
